Mondorf A W, Buch A, Steinbacher G, Rüdel C, Falkenberg F W
Abteilung für Nephrologie, Klinikum der J. W. Goethe Universität, Frankfurt/Main, Federal Republic of Germany.
J Antimicrob Chemother. 1988 Oct;22 Suppl D:179-89. doi: 10.1093/jac/22.supplement_d.179.
In order to evaluate kidney tolerance of fleroxacin, a new fluoroquinolone, we performed a volunteer study with 16 healthy males, 20-27 years old. On three consecutive days 800 mg of fleroxacin was administered orally. Alanine-aminopeptidase and distal- and pan-tubular antigens were determined in 24 h urine collections with specific monoclonal antibodies. Routine haematological and biochemical parameters were determined daily and were in the normal range during the follow-up. No significant changes in excretion of alanine-aminopeptidase and of the urinary antigens were observed during the three days of fleroxacin administration and on the following three days. The results obtained in this volunteer study indicate that fleroxacin has no nephrotoxic side effects.
为了评估新型氟喹诺酮类药物氟罗沙星对肾脏的耐受性,我们对16名年龄在20至27岁之间的健康男性进行了一项志愿者研究。连续三天口服800毫克氟罗沙星。用特异性单克隆抗体在24小时尿液收集物中测定丙氨酸氨基肽酶以及远曲小管和全肾小管抗原。每天测定常规血液学和生化参数,在随访期间这些参数均在正常范围内。在给予氟罗沙星的三天期间以及随后的三天内,未观察到丙氨酸氨基肽酶排泄和尿抗原的显著变化。在这项志愿者研究中获得的结果表明,氟罗沙星没有肾毒性副作用。